Skip to main content
SpringerLink
Log in

Adjunct Drug Treatment to Reduce Vascular Disease in People with Diabetes

  • Chapter
  • First Online:
Lipoproteins in Diabetes Mellitus

Part of the book series: Contemporary Diabetes ((CDI))

  • 388 Accesses

Abstract

There is a pandemic of diabetes mellitus, and with it comes the risk of chronic neurovascular complications of diabetes, which greatly increases the personal and socioeconomic burden of diabetes. The development and progression of cardiovascular disease, including coronary artery disease, heart failure, cerebrovascular disease, peripheral vascular disease diabetic retinopathy, nephropathy, and neuropathy, can be prevented, or at least retarded if there is optimal control of the many related risk factors. An increasing range of proven lifestyles, medications, and technologies are available to optimize these risk factors, but to do so requires input from people with diabetes, their carers, multidisciplinary clinicians, healthcare system, health insurance providers, community, and government. Many people with diabetes and their clinicians take a very glucose-centric view of diabetes care, and whilst very important, the management of other risk factors, such as lipids, the focus of this book, and of hypertension and many lifestyle-related risk factors is also key, and often less challenging to optimize. An updated mnemonic to remind clinicians and trainees of the many facets to consider in diabetes care is GLOBES CAD STRIVE, representing Glucose, Lipids and lipid drugs, Obesity, Blood pressure and blood pressure drugs, Emotions, and Smoking (GLOBES); Clotting, Advocacy, and Devices (CAD); and Screening TReating to target, Infection, Vaccination, and Education (STRIVE). Each of these elements is briefly overviewed in this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. International Diabetes Federation. IDF diabetes atlas, 10th ed. Brussels, Belgium; 2021. https://www.diabetesatlas.org.

  2. Middleton TL, Chadban S, Molyneaux L, D’Souza M, Constantino MI, Yue DK, McGill M, Wu T, Twigg SM, Wong J. Young adult onset type 2 diabetes versus type 1 diabetes: progression to and survival on renal replacement therapy. J Diabetes Complicat. 2021;35(11):108023. https://doi.org/10.1016/j.jdiacomp.2021.108023. Epub 2021 Aug 19.

    Article  CAS  Google Scholar 

  3. Middleton TL, Constantino MI, Molyneaux L, D’Souza M, Twigg SM, Wu T, Yue DK, Zoungas S, Wong J. Young-onset type 2 diabetes and younger current age: increased susceptibility to retinopathy in contrast to other complications. Diabet Med. 2020;37(6):991–9. https://doi.org/10.1111/dme.14238. Epub 2020 Feb 5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Constantino MI, Molyneaux L, Limacher-Gisler F, Al-Saeed A, Luo C, Wu T, Twigg SM, Yue DK, Wong J. Long-term complications and mortality in young-onset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes. Diabetes Care. 2013;36(12):3863–9. https://doi.org/10.2337/dc12-2455. Epub 2013 Jul 11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Harding JL, Wander PL, Zhang X, Li X, Karuranga S, Chen H, Sun H, Xie Y, Oram RA, Magliano DJ, Zhou Z, Jenkins AJ, Ma RCW. The incidence of adult-onset type 1 diabetes: a systematic review from 32 countries and regions. Diabetes Care. 2022;45(4):994–1006. https://doi.org/10.2337/dc21-1752.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Jenkins A, Scott E, Fulcher J, Kilov G, Januszewski A. Management of diabetes. In: Toth P, Canon C, editors. Comprehensive cardiovascular medicine in the primary care setting. Humana Press; Jan 2019.

    Google Scholar 

  7. Rawshani A, Sattar N, Franzén S, Rawshani A, Hattersley AT, Svensson A-M, et al. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet. 2018;392(10146):477–86. https://doi.org/10.1016/s0140-6736(18)31506-x.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Pemayun TG, Naibaho RM, Novitasari D, Amin N, Minuljo TT. Risk factors for lower extremity amputation in patients with diabetic foot ulcers: a hospital- based case-control study. Diabet Foot Ankle. 2015;6:29629. https://doi.org/10.3402/dfa.v6.29629.

    Article  PubMed  Google Scholar 

  9. https://www.nei.nih.gov/learn-about-eye-health/outreach-campaigns-and-resources/eye-health-data-and-statistics/diabetic-retinopathy-data-and-statistics. Accessed 14 May 2022.

  10. https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/diabetic-kidney-disease#. Accessed 14 May 2022.

  11. The Royal Australian College of General Practitioners. Management of type 2 diabetes: a handbook for general practice. East Melbourne, Vic: RACGP; 2020.

    Google Scholar 

  12. Australian Institute of Health and Welfare. Cardiovascular disease, diabetes and chronic kidney disease: Australian facts mortality. 2014. https://www.aihw.gov.au/reports/heart-stroke-vascular-disease/cardiovascular-diabetes-chronic-kidney-mortality/contents/table-of-contents.

  13. Lempiäinen PA, Vasunta RL, Bloigu R, Kesäniemi YA, Ukkola OH. Non-dipping blood pressure pattern and new-onset diabetes in a 21-year follow-up. Blood Press. 2019;28(5):300–8. https://doi.org/10.1080/08037051.2019.1615369. Epub 2019 May 15.

    Article  PubMed  Google Scholar 

  14. Klatman EL, Jenkins AJ, Ahmedani MY, Ogle GD. Blood glucose meters and test strips: global market and challenges to access in low-resource settings. Lancet Diabetes Endocrinol. 2019;7(2):150–60. https://doi.org/10.1016/S2213-8587(18)30074-3. Epub 2018 Jul 30. Erratum in: Lancet Diabetes Endocrinol. 2018 Aug 30.

    Article  PubMed  Google Scholar 

  15. Brennan F, Williams P, Armstrong K, Klatman E, Donelan N, Ogle GD, Eussen A, Jenkins AJ. A human rights-based approach to improve access to insulin and other aspects of diabetes care. Diabetes Res Clin Pract. 2022;183:109153. https://doi.org/10.1016/j.diabres.2021.109153. Epub 2021 Nov 24.

    Article  PubMed  Google Scholar 

  16. Fralick M, Jenkins AJ, Khunti K, Mbanya JC, Mohan V, Schmidt MI. Global accessibility of therapeutics for diabetes mellitus. Nat Rev Endocrinol. 2022;18(4):199–204. https://doi.org/10.1038/s41574-021-00621-y. Epub 2022 Jan 17.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–91.

    Article  CAS  PubMed  Google Scholar 

  18. Jenkins AJ, Januszewski AS, O’Neal DN. Addressing vascular risk factors in diabetes. Endocrinol Today. 2015;4(4):35–8.

    Google Scholar 

  19. Chen D, Fulcher J, Scott ES, Jenkins AJ. Precision medicine approaches for management of type 2 diabetes. In: Basu R, editor. Precision medicine diabetes: a multidisciplinary approach to an emerging paradigm; 2022. p. 1–52.

    Google Scholar 

  20. Classification and diagnosis of diabetes: standards of medical care in diabetes—2021. Am Diabetes Assoc Diabetes Care. 2021;44(Suppl. 1):S15–33. https://doi.org/10.2337/dc21-S002.

  21. Lin R, Brown F, James S, Jones J, Ekinci E. Continuous glucose monitoring: a review of the evidence in type 1 and 2 diabetes mellitus. Diabet Med. 2021;38(5):e14528. https://doi.org/10.1111/dme.14528. Epub 2021 Mar 6.

    Article  CAS  PubMed  Google Scholar 

  22. Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, Garg S, Heinemann L, Hirsch I, Amiel SA, Beck R, Bosi E, Buckingham B, Cobelli C, Dassau E, Doyle FJ 3rd, Heller S, Hovorka R, Jia W, Jones T, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Maahs D, Murphy HR, Nørgaard K, Parkin CG, Renard E, Saboo B, Scharf M, Tamborlane WV, Weinzimer SA, Phillip M. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40(12):1631–40. https://doi.org/10.2337/dc17-1600.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Maiorino MI, Signoriello S, Maio A, Chiodini P, Bellastella G, Scappaticcio L, Longo M, Giugliano D, Esposito K. Effects of continuous glucose monitoring on metrics of glycemic control in diabetes: a systematic review with meta-analysis of randomized controlled trials. Diabetes Care. 2020;43(5):1146–56. https://doi.org/10.2337/dc19-1459.

    Article  CAS  PubMed  Google Scholar 

  24. Mian Z, Hermayer KL, Jenkins A. Continuous glucose monitoring: review of an innovation in diabetes management. Am J Med Sci. 2019;358(5):332–9. https://doi.org/10.1016/j.amjms.2019.07.003. Epub 2019 Jul 17.

    Article  PubMed  Google Scholar 

  25. Johnson ML, Martens TW, Criego AB, Carlson AL, Simonson GD, Bergenstal RM. Utilizing the ambulatory glucose profile to standardize and implement continuous glucose monitoring in clinical practice. Diabetes Technol Ther. 2019;21(S2):S217–25. https://doi.org/10.1089/dia.2019.0034.

    Article  PubMed  Google Scholar 

  26. Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, Bosi E, Buckingham BA, Cefalu WT, Close KL, Cobelli C, Dassau E, JH DV, Donaghue KC, Dovc K, Doyle FJ 3rd, Garg S, Grunberger G, Heller S, Heinemann L, Hirsch IB, Hovorka R, Jia W, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Levine B, Mayorov A, Mathieu C, Murphy HR, Nimri R, Nørgaard K, Parkin CG, Renard E, Rodbard D, Saboo B, Schatz D, Stoner K, Urakami T, Weinzimer SA, Phillip M. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593–603. https://doi.org/10.2337/dci19-0028. Epub 2019 Jun 8.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Gorst C, Kwok CS, Aslam S, Buchan I, Kontopantelis E, Myint PK, Heatlie G, Loke Y, Rutter MK, Mamas MA. Long-term glycemic variability and risk of adverse outcomes: a systematic review and meta-analysis. Diabetes Care. 2015;38(12):2354–69. https://doi.org/10.2337/dc15-1188.

    Article  CAS  PubMed  Google Scholar 

  28. Guo K, Zhao Q, Wang M, Lu Y, Wo M, Zhou X, Ying C. The scope of HbA1c variability and risk of vascular complications among patients with type 2 diabetes: a systematic review and meta-analysis of prospective studies. Horm Metab Res. 2022;54(2):94–103. https://doi.org/10.1055/a-1730-4904. Epub 2022 Feb 7.

    Article  CAS  PubMed  Google Scholar 

  29. Scott ES, Januszewski AS, O’Connell R, Fulcher G, Scott R, Kesaniemi A, Wu L, Colagiuri S, Keech A, Jenkins AJ. Long-term glycemic variability and vascular complications in type 2 diabetes: post hoc analysis of the FIELD study. J Clin Endocrinol Metab. 2020;105(10):dgaa361. https://doi.org/10.1210/clinem/dgaa361.

    Article  PubMed  Google Scholar 

  30. Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, Hayward RA, Craven T, Coleman RL, Chalmers J. Collaborators on trials of lowering glucose g. effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5(6):431–7.

    Article  PubMed  Google Scholar 

  31. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373(9677):1765–72.

    Article  CAS  PubMed  Google Scholar 

  32. International Hypoglycaemia Study Group. Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol. 2019;7(5):385–96. https://doi.org/10.1016/S2213-8587(18)30315-2. Epub 2019 Mar 27. Erratum in: Lancet Diabetes Endocrinol. 2019 Jun;7(6):e18.

    Article  Google Scholar 

  33. Ceriello A, Novials A, Ortega E, La Sala L, Pujadas G, Testa R, Bonfigli AR, Esposito K, Giugliano D. Evidence that hyperglycemia after recovery from hypoglycemia worsens endothelial function and increases oxidative stress and inflammation in healthy control subjects and subjects with type 1 diabetes. Diabetes. 2012;61(11):2993–7. https://doi.org/10.2337/db12-0224. Epub 2012 Aug 13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Wright RJ, Newby DE, Stirling D, Ludlam CA, Macdonald IA, Frier BM. Effects of acute insulin-induced hypoglycemia on indices of inflammation: putative mechanism for aggravating vascular disease in diabetes. Diabetes Care. 2010;33(7):1591–7. https://doi.org/10.2337/dc10-0013.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Bedenis R, Price AH, Robertson CM, Morling JR, Frier BM, Strachan MW, Price JF. Association between severe hypoglycemia, adverse macrovascular events, and inflammation in the Edinburgh type 2 diabetes study. Diabetes Care. 2014;37(12):3301–8. https://doi.org/10.2337/dc14-0908. Epub 2014 Sep 19.

    Article  PubMed  Google Scholar 

  36. Heller SR. Abnormalities of the electrocardiogram during hypoglycaemia: the cause of the dead in bed syndrome? Int J Clin Pract Suppl. 2002;129:27–32.

    Google Scholar 

  37. Tanenberg RJ, Newton CA, Drake AJ. Confirmation of hypoglycemia in the “dead- in-bed” syndrome, as captured by a retrospective continuous glucose monitoring system. Endocr Pract. 2010;16(2):244–8. https://doi.org/10.4158/EP09260.CR.

    Article  PubMed  Google Scholar 

  38. Hsieh A, Twigg SM. The enigma of the dead-in-bed syndrome: challenges in predicting and preventing this devastating complication of type 1 diabetes. J Diabetes Complicat. 2014;28(5):585–7. https://doi.org/10.1016/j.jdiacomp.2014.04.005. Epub 2014 Apr 18

    Article  Google Scholar 

  39. Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86. https://doi.org/10.1056/NEJM199309303291401.

    Article  Google Scholar 

  40. Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44(8):968–83.

    Article  Google Scholar 

  41. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B. Diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study research group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643–53. https://doi.org/10.1056/NEJMoa052187.

    Article  PubMed  Google Scholar 

  42. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK prospective diabetes study (UKPDS) group. Lancet. 1998;352(9131):837–53.

    Google Scholar 

  43. Hayward RA, Reaven PD, Wiitala WL, Bahn GD, Reda DJ, Ge L, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;372(23):2197–206.

    Article  CAS  PubMed  Google Scholar 

  44. Lachin JM, Nathan DM, DCCT/EDIC Research Group. Understanding metabolic memory: the prolonged influence of glycemia during the diabetes control and complications trial (DCCT) on future risks of complications during the study of the epidemiology of diabetes interventions and complications (EDIC). Diabetes Care. 2021;44(10):2216–24. https://doi.org/10.2337/dc20-3097. Epub ahead of print.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Chalmers J, Cooper ME. UKPDS and the legacy effect. N Engl J Med. 2008;359(15):1618–20. https://doi.org/10.1056/NEJMe0807625.

    Article  CAS  PubMed  Google Scholar 

  46. Murray P, Chune GW, Raghavan VA. Legacy effects from DCCT and UKPDS: what they mean and implications for future diabetes trials. Curr Atheroscler Rep. 2010;12(6):432–9. https://doi.org/10.1007/s11883-010-0128-1.

    Article  PubMed  Google Scholar 

  47. Qaseem A, Wilt TJ, Kansagara D, Horwitch C, Barry MJ, Forciea MA, Clinical Guidelines Committee of the American College of Physicians, Fitterman N, Balzer K, Boyd C, Humphrey LL, Iorio A, Lin J, Maroto M, McLean R, Mustafa R, Tufte J. Hemoglobin A1c targets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus: a guidance statement update from the American college of physicians. Ann Intern Med. 2018;168(8):569–76. https://doi.org/10.7326/M17-0939. Epub 2018 Mar 6.

    Article  PubMed  Google Scholar 

  48. Butler AE, English E, Kilpatrick ES, Östlundh L, Chemaitelly HS, Abu-Raddad LJ, Alberti KGMM, Atkin SL, John WG. Diagnosing type 2 diabetes using hemoglobin A1c: a systematic review and meta-analysis of the diagnostic cutpoint based on microvascular complications. Acta Diabetol. 2021;58(3):279–300. https://doi.org/10.1007/s00592-020-01606-5. Epub 2020 Nov 3.

    Article  CAS  PubMed  Google Scholar 

  49. Sinha B, Ghosal S. A target HbA1c between 7 and 7.7% reduces microvascular and macrovascular events in T2D regardless of duration of diabetes: a meta-analysis of randomized controlled trials. Diabetes Ther. 2021;12(6):1661–76. https://doi.org/10.1007/s13300-021-01062-6. Epub 2021 Apr 24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Cheung NW, Conn JJ, d’Emden MC, Gunton JE, Jenkins AJ, Ross GP, Sinha AK, Andrikopoulos S, Colagiuri S, Twigg SM, Australian Diabetes Society. Position statement of the Australian Diabetes Society: individualisation of glycated haemoglobin targets for adults with diabetes mellitus. Med J Aust. 2009;191(6):339–44. https://doi.org/10.5694/j.1326-5377.2009.tb02819.x.

    Article  PubMed  Google Scholar 

  51. Herrington WG, Preiss D, Haynes R, von Eynatten M, Staplin N, Hauske SJ, George JT, Green JB, Landray MJ, Baigent C, Wanner C. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. Clin Kidney J. 2018;11(6):749–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Kristensen SL, Rorth R, Jhund PS, Docherty KF, Sattar N, Preiss D, Kober L, Petrie MC, McMurray JJV. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776–85.

    Article  CAS  PubMed  Google Scholar 

  53. Australian diabetes society type 2 diabetes treatment algorithm. https://t2d.diabetessociety.com.au/plan/. Accessed 14 May 2022.

  54. AACE comprehensive type 2 diabetes management algorithm. https://pro.aace.com/pdfs/diabetes/AACE_2019_Diabetes_Algorithm_03.2021.pdf. Accessed 15 May 2022.

  55. Steineck I, Cederholm J, Eliasson B, Rawshani A, Eeg-Olofsson K, Svensson AM, et al. Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18,168 people with type 1 diabetes: observational study. BMJ. 2015;350:h3234. https://doi.org/10.1136/bmj.h3234.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Virk SA, Donaghue KC, Wong TY, Craig ME. Interventions for diabetic retinopathy in type 1 diabetes: systematic review and meta-analysis. Am J Ophthalmol. 2015;160(5):1055–64 e4. https://doi.org/10.1016/j.ajo.2015.07.024.

    Article  PubMed  Google Scholar 

  57. Zabeen B, Craig ME, Virk SA, Pryke A, Chan AK, Cho YH, et al. Insulin pump therapy is associated with lower rates of retinopathy and peripheral nerve abnormality. PLoS One. 2016;11(4):e0153033. https://doi.org/10.1371/journal.pone.0153033.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Avgerinos I, Manolopoulos A, Michailidis T, Kitsios K, Liakos A, Karagiannis T, Dimitrakopoulos K, Matthews DR, Tsapas A, Bekiari E. Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: a systematic review and network meta-analysis. Diabetes Obes Metab. 2021;23(3):822–31. https://doi.org/10.1111/dom.14291. Epub 2021 Jan 6.

    Article  CAS  PubMed  Google Scholar 

  59. Goyal I, Sattar A, Johnson M, Dandona P. Adjunct therapies in treatment of type 1 diabetes. J Diabetes. 2020;12(10):742–53. https://doi.org/10.1111/1753-0407.13078. Epub 2020 Sep 9.

    Article  CAS  PubMed  Google Scholar 

  60. Lane K, Freeby M. Adjunctive therapies in type 1 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2021;28(1):8–13. https://doi.org/10.1097/MED.0000000000000602.

    Article  CAS  PubMed  Google Scholar 

  61. Petrie JR, Chaturvedi N, Ford I, Brouwers MCGJ, Greenlaw N, Tillin T, Hramiak I, Hughes AD, Jenkins AJ, Klein BEK, Klein R, Ooi TC, Rossing P, Stehouwer CDA, Sattar N, Colhoun HM, REMOVAL Study Group. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5(8):597–609. https://doi.org/10.1016/S2213-8587(17)30194-8. Epub 2017 Jun 11

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Timmons JG, Greenlaw N, Boyle JG, Chaturvedi N, Ford I, Brouwers MCGJ, Tillin T, Hramiak I, Hughes AD, Jenkins AJ, Klein BEK, Klein R, Ooi TC, Rossing P, Stehouwer CDA, Sattar N, Colhoun HM, Petrie JR, REMOVAL Study Group. Metformin and carotid intima-media thickness in never-smokers with type 1 diabetes: the REMOVAL trial. Diabetes Obes Metab. 2021;23(6):1371–8. https://doi.org/10.1111/dom.14350. Epub 2021 Mar 8.

    Article  CAS  PubMed  Google Scholar 

  63. Livingstone R, Boyle JG, Petrie JR, REMOVAL Study Team. A new perspective on metformin therapy in type 1 diabetes. Diabetologia. 2017;60(9):1594–600. https://doi.org/10.1007/s00125-017-4364-6. Epub 2017 Aug 2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Taylor SI, Blau JE, Rother KI, Beitelshees AL. SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks. Lancet Diabetes Endocrinol. 2019;7(12):949–58. https://doi.org/10.1016/S2213-8587(19)30154-8. Epub 2019 Oct 1.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Paik J, Blair HA. Dapagliflozin: a review in type 1 diabetes. Drugs. 2019;79(17):1877–84. https://doi.org/10.1007/s40265-019-01213-x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Haidar A, Lovblom LE, Cardinez N, et al. Empagliflozin add-on therapy to closed-loop insulin delivery in type 1 diabetes: a 2 × 2 factorial randomized crossover trial. Nat Med. 2022;28:1269. https://doi.org/10.1038/s41591-022-01805-3.

    Article  CAS  PubMed  Google Scholar 

  67. Albèr A, Brønden A, Knop FK. Short-acting glucagon-like peptide-1 receptor agonists as add-on to insulin therapy in type 1 diabetes: a review. Diabetes Obes Metab. 2017;19(7):915–25. https://doi.org/10.1111/dom.12911. Epub 2017 Mar 17.

    Article  CAS  PubMed  Google Scholar 

  68. Dimitrios P, Michael D, Vasilios K, Konstantinos S, Konstantinos I, Ioanna Z, Konstantinos P, Spyridon B, Asterios K. Liraglutide as adjunct to insulin treatment in patients with type 1 diabetes: a systematic review and meta-analysis. Curr Diabetes Rev. 2020;16(4):313–26. https://doi.org/10.2174/1573399815666190614141918.

    Article  PubMed  Google Scholar 

  69. Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, Weyer C, Kolterman OG. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med. 2004;21(11):1204–12. https://doi.org/10.1111/j.1464-5491.2004.01319.x.

    Article  CAS  PubMed  Google Scholar 

  70. Jenkins AJ, Best JD, Klein RL, Lyons TJ. Lipoproteins, glycoxidation and diabetic angiopathy. Diabetes Metab Res Rev. 2004;20(5):349–68. https://doi.org/10.1002/dmrr.491.

    Article  CAS  PubMed  Google Scholar 

  71. Jenkins AJ, Rowley KG, Lyons TJ, Best JD, Hill MA, Klein RL. Lipoproteins and diabetic microvascular complications. Curr Pharm Des. 2004;10(27):3395–418. https://doi.org/10.2174/1381612043383188.

    Article  CAS  PubMed  Google Scholar 

  72. Klein RL, Carter RE, Jenkins AJ, Lyons TJ, Baker NL, Gilbert GE, Virella G, Lopes-Virella MF, DCCT/EDIC Research Group. LDL-containing immune complexes in the DCCT/EDIC cohort: associations with lipoprotein subclasses. J Diabetes Complicat. 2011;25(2):73–82. https://doi.org/10.1016/j.jdiacomp.2010.03.001. Epub 2010 Jun 3.

    Article  Google Scholar 

  73. Jenkins AJ, Grant MB, Busik JV. Lipids, hyperreflective crystalline deposits and diabetic retinopathy: potential systemic and retinal-specific effect of lipid-lowering therapies. Diabetologia. 2022;65(4):587–603. https://doi.org/10.1007/s00125-022-05655-z. Epub 2022 Feb 11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Noonan JE, Jenkins AJ, Ma JX, Keech AC, Wang JJ, Lamoureux EL. An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. Diabetes. 2013;62(12):3968–75. https://doi.org/10.2337/db13-0800.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Sivashanmugarajah A, Fulcher J, Sullivan D, Elam M, Jenkins A, Keech A. Suggested clinical approach for the diagnosis and management of ‘statin intolerance’ with an emphasis on muscle-related side-effects. Intern Med J. 2019;49(9):1081–91. https://doi.org/10.1111/imj.14429.

    Article  PubMed  Google Scholar 

  76. Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL 2nd, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK, American Heart Association Clinical Lipidology, Lipoprotein, Metabolism and Thrombosis Committee, a Joint Committee of the Council on Atherosclerosis, Thrombosis and Vascular Biology and Council on Lifestyle and Cardiometabolic Health, Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Stroke Council. Statin safety and associated adverse events: a scientific statement from the American heart association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38–81. https://doi.org/10.1161/ATV.0000000000000073.

    Article  CAS  PubMed  Google Scholar 

  77. Kajinami K, Tsukamoto K, Koba S, Inoue I, Yamakawa M, Suzuki S, Hamano T, Saito H, Saito Y, Masuda S, Nakayama T, Okamura T, Yamashita S, Kagawa T, Kaneyama J, Kuriyama A, Tanaka R, Hirata A, Statin Intolerance Clinical Guide Working Group, The Japan Society of Hepatology, Japanese Society of Neurology, Japan Atherosclerosis Society, The Japanese Society for the Study of Xenobiotics. Statin Intolerance Clinical Guide 2018. J Atheroscler Thromb. 2020;27(4):375–96. https://doi.org/10.5551/jat.50948. Epub 2019 Oct 4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Drexel H, Coats AJS, Spoletini I, Bilato C, Mollace V, Perrone Filardi P, Rosano GMC. An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC working group on cardiovascular pharmacotherapy: barriers to be overcome. Eur Heart J Cardiovasc Pharmacother. 2020;6(2):115–21. https://doi.org/10.1093/ehjcvp/pvz079. Erratum in: Eur Heart J Cardiovasc Pharmacother 2020 Sep 1;6(5):291.

    Article  PubMed  Google Scholar 

  79. Susekov AV, Korol LA, Watts GF. Bempedoic acid in the treatment of patients with dyslipidemias and statin intolerance. Cardiovasc Drugs Ther. 2021;35(4):841–52. https://doi.org/10.1007/s10557-020-07139-x. Epub 2021 Jan 27.

    Article  CAS  PubMed  Google Scholar 

  80. Kietsiriroje N, Pearson S, Campbell M, Ariëns RAS, Ajjan RA. Double diabetes: a distinct high-risk group? Diabetes Obes Metab. 2019;21(12):2609–18. https://doi.org/10.1111/dom.13848. Epub 2019 Aug 19.

    Article  CAS  PubMed  Google Scholar 

  81. Cleland SJ, Fisher BM, Colhoun HM, Sattar N, Petrie JR. Insulin resistance in type 1 diabetes: what is ‘double diabetes’ and what are the risks? Diabetologia. 2013;56(7):1462–70. https://doi.org/10.1007/s00125-013-2904-2. Epub 2013 Apr 24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Khawandanah J. Double or hybrid diabetes: a systematic review on disease prevalence, characteristics and risk factors. Nutr Diabetes. 2019;9(1):33. https://doi.org/10.1038/s41387-019-0101-1.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Januszewski AS, Sachithanandan N, Ward G, Karschimkus CS, O’Neal DN, Jenkins AJ. Estimated insulin sensitivity in type 1 diabetes adults using clinical and research biomarkers. Diabetes Res Clin Pract. 2020;167:108359. https://doi.org/10.1016/j.diabres.2020.108359. Epub 2020 Jul 31.

    Article  CAS  PubMed  Google Scholar 

  84. Tay J, Luscombe-Marsh ND, Thompson CH, Noakes M, Buckley JD, Wittert GA, Yancy WS Jr, Brinkworth GD. Comparison of low- and high-carbohydrate diets for type 2 diabetes management: a randomized trial. Am J Clin Nutr. 2015;102(4):780–90.

    Article  CAS  PubMed  Google Scholar 

  85. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Nanni G, Castagneto M, Bornstein S, Rubino F. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2015;386(9997):964–73.

    Article  PubMed  Google Scholar 

  86. Mottalib A, Kasetty M, Mar JY, Elseaidy T, Ashrafzadeh S, Hamdy O. Weight management in patients with type 1 diabetes and obesity. Curr Diab Rep. 2017;17(10):92. https://doi.org/10.1007/s11892-017-0918-8.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Van der Schueren B, Ellis D, Faradji RN, Al-Ozairi E, Rosen J, Mathieu C. Obesity in people living with type 1 diabetes. Lancet Diabetes Endocrinol. 2021;9(11):776–85. https://doi.org/10.1016/S2213-8587(21)00246-1. Epub 2021 Sep 30.

    Article  PubMed  Google Scholar 

  88. Korakas E, Kountouri A, Raptis A, Kokkinos A, Lambadiari V. Bariatric surgery and type 1 diabetes: unanswered questions. Front Endocrinol. 2020;11:525909. https://doi.org/10.3389/fendo.2020.525909.

    Article  Google Scholar 

  89. Ashrafian H, Harling L, Toma T, Athanasiou C, Nikiteas N, Efthimiou E, Darzi A, Athanasiou T. Type 1 diabetes mellitus and bariatric surgery: a systematic review and meta-analysis. Obes Surg. 2016;26(8):1697–704. https://doi.org/10.1007/s11695-015-1999-6.

    Article  PubMed  Google Scholar 

  90. Hwang Y, Khasag A, Jia W, Jenkins A, Huang CN, Yabe D, Kim DM, Kadowaki T, Lee MK. Diabetes and COVID-19: IDF perspective in the Western Pacific region. Diabetes Res Clin Pract. 2020;166:108278. https://doi.org/10.1016/j.diabres.2020.108278. Epub 2020 Jun 25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Scott ES, Jenkins AJ, Fulcher GR. Challenges of diabetes management during the COVID-19 pandemic. Med J Aust. 2020;213(2):56–57.e1. https://doi.org/10.5694/mja2.50665. Epub 2020 Jun 24.

    Article  PubMed  Google Scholar 

  92. Venkatesh N, Paldus B, Lee MH, MacIsaac RJ, Jenkins AJ, O’Neal DN. COVID-19, type 1 diabetes clinical practice, research, and remote medical care: a view from the land down-under. J Diabetes Sci Technol. 2020;14(4):803–4. https://doi.org/10.1177/1932296820929708. Epub 2020 May 29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Turnbull F. Blood pressure lowering treatment trialist’s collaboration: effects of different blood pressure-lowering regimens on majore cardiovascular events: results of prospectively designed overviews of randomised trials. Lanet. 2003;362:1527–35.

    Google Scholar 

  94. American Diabetes Association. 2022 Standards of medical care in diabetes 2022. https://diabetesjournals.org/clinical/article/40/1/10/139035/Standards-of-Medical-Care-in-Diabetes-2022. Accessed 15 May 2022.

  95. Group AS, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575–85.

    Article  Google Scholar 

  96. Carey RM, Wright JT Jr, Taler SJ, Whelton PK. Guideline-driven management of hypertension: an evidence-based update. Circ Res. 2021;128(7):827–46. https://doi.org/10.1161/CIRCRESAHA.121.318083. Epub 2021 Apr 1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Jones NR, McCormack T, Constanti M, McManus RJ. Diagnosis and management of hypertension in adults: NICE guideline update 2019. Br J Gen Pract. 2020;70(691):90–1. https://doi.org/10.3399/bjgp20X708053.

    Article  PubMed  PubMed Central  Google Scholar 

  98. Guerrero-Garcia C, Rubio-Guerra AF. Combination therapy in the treatment of hypertension. Drugs Context. 2018;7:212531.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Hermida RC, Ayala DE, Mojon A, Fernandez JR. Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care. 2011;34(6):1270–6.

    Article  PubMed  PubMed Central  Google Scholar 

  100. Nanayakkara N, Pease A, Ranasinha S, Wischer N, Andrikopoulos S, Speight J, de Courten B, Zoungas S. Depression and diabetes distress in adults with type 2 diabetes: results from the Australian National Diabetes Audit (ANDA) 2016. Sci Rep. 2018;8(1):7846.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Dennick K, Sturt J, Speight J. What is diabetes distress and how can we measure it? A narrative review and conceptual model. J Diabetes Complicat. 2017;31(5):898–911. https://doi.org/10.1016/j.jdiacomp.2016.12.018. Epub 2017 Feb 14.

    Article  Google Scholar 

  102. Hendrieckx C, Halliday JA, Russell-Green S, Cohen N, Colman PG, Jenkins A, O’Neal D, Speight J. Adults with diabetes distress often want to talk with their health professionals about it: findings from an audit of 4 Australian specialist diabetes clinics. Can J Diabetes. 2020. https://doi.org/10.1016/j.jcjd.2020.02.004.

  103. Perrin NE, Davies MJ, Robertson N, Snoek FJ, Khunti K. The prevalence of diabetes-specific emotional distress in people with type 2 diabetes: a systematic review and meta-analysis. Diabet Med. 2017;34(11):1508–20. https://doi.org/10.1111/dme.13448. Epub 2017 Aug 31.

    Article  CAS  PubMed  Google Scholar 

  104. Fisher L, Polonsky WH, Hessler D. Addressing diabetes distress in clinical care: a practical guide. Diabet Med. 2019;36(7):803–12. https://doi.org/10.1111/dme.13967. Epub 2019 May 7.

    Article  CAS  PubMed  Google Scholar 

  105. Hagger V, Hendrieckx C, Sturt J, Skinner TC, Speight J. Diabetes distress among adolescents with type 1 diabetes: a systematic review. Curr Diab Rep. 2016;16(1):9. https://doi.org/10.1007/s11892-015-0694-2.

    Article  PubMed  Google Scholar 

  106. Kenny E, O’Malley R, Roche K, Morrissey E, Dinneen SF, Byrne M, Casey B. Diabetes distress instruments in adults with Type 1 diabetes: a systematic review using the COSMIN (COnsensus-based Standards for the selection of health status Measurement INstruments) checklist. Diabet Med. 2021;38(4):e14468. https://doi.org/10.1111/dme.14468. Epub 2020 Dec 2.

    Article  PubMed  Google Scholar 

  107. Winkley K, Upsher R, Stahl D, Pollard D, Kasera A, Brennan A, Heller S, Ismail K. Psychological interventions to improve self-management of type 1 and type 2 diabetes: a systematic review. Health Technol Assess. 2020;24(28):1–232. https://doi.org/10.3310/hta24280.

    Article  PubMed  PubMed Central  Google Scholar 

  108. Holt RIG. Association between antipsychotic medication use and diabetes. Curr Diab Rep. 2019;19(10):96. https://doi.org/10.1007/s11892-019-1220-8.

    Article  PubMed  PubMed Central  Google Scholar 

  109. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA. 2003;290(1):86–97.

    Article  PubMed  Google Scholar 

  110. Wilkes S, Evans A. A cross-sectional study comparing the motivation for smoking cessation in apparently healthy patients who smoke to those who smoke and have ischaemic heart disease, hypertension or diabetes. Fam Pract. 1999;16(6):608–10.

    Article  CAS  PubMed  Google Scholar 

  111. West R. Tobacco smoking: health impact, prevalence, correlates and interventions. Psychol Health. 2017;32(8):1018–36.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Kalkhoran S, Glantz SA. E-cigarettes and smoking cessation in real-world and clinical settings: a systematic review and meta-analysis. Lancet Respir Med. 2016;4(2):116–28.

    Article  PubMed  PubMed Central  Google Scholar 

  113. Alzahrani T, Pena I, Temesgen N, Glantz SA. Association between electronic cigarette use and myocardial infarction. Am J Prev Med. 2018;55(4):455–61. https://doi.org/10.1016/j.amepre.2018.05.004. Epub 2018 Aug 22

    Article  PubMed  PubMed Central  Google Scholar 

  114. Górna I, Napierala M, Florek E. Electronic cigarette use and metabolic syndrome development: a critical review. Toxics. 2020;8(4):105. https://doi.org/10.3390/toxics8040105.

    Article  PubMed  PubMed Central  Google Scholar 

  115. McNeil JJ, Nelson MR, Woods RL, Lockery JE, Wolfe R, Reid CM, et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med. 2018;379(16):1519–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, Howard G, Pearson TA, Rothwell PM, Ruilope LM, Tendera M, Tognoni G, ARRIVE Executive Committee. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392(10152):1036–46. https://doi.org/10.1016/S0140-6736(18)31924-X. Epub 2018 Aug 26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Jenkins AJ. Sometimes you have to give a man a fish. Med J Aust. 2014;200(2):122–3. https://doi.org/10.5694/mja13.10813.

    Article  PubMed  Google Scholar 

  118. Jenkins A. The world I want—a world with less diabetes. Med J Aust. 2015;202(2):108–9. https://doi.org/10.5694/mja14.00835.

    Article  PubMed  Google Scholar 

  119. Antithrombotic Trialists Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–60.

    Article  CAS  Google Scholar 

  120. Ascend Study Collaborative Group, Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379(16):1529–39.

    Article  Google Scholar 

  121. Broadbent DM, Wang A, Cheyne CP, James M, Lathe J, Stratton IM, Roberts J, Moitt T, Vora JP, Gabbay M, García-Fiñana M, Harding SP, ISDR Study Group. Safety and cost-effectiveness of individualised screening for diabetic retinopathy: the ISDR open-label, equivalence RCT. Diabetologia. 2021;64(1):56–69. https://doi.org/10.1007/s00125-020-05313-2. Epub 2020 Nov 4.

    Article  PubMed  Google Scholar 

  122. Marchand L, Disse E, Dalle S, Reffet S, Vouillarmet J, Fabien N, Thivolet C, Cugnet-Anceau C. The multifaceted nature of diabetes mellitus induced by checkpoint inhibitors. Acta Diabetol. 2019;56(12):1239–45. https://doi.org/10.1007/s00592-019-01402-w. Epub 2019 Aug 19.

    Article  PubMed  Google Scholar 

  123. Atkinson-Briggs S, Jenkins A, Ryan C, Brazionis L. Centre for research excellence in diabetic retinopathy study group. Health-risk behaviours among indigenous Australians with diabetes: a study in the integrated diabetes education and eye screening (iDEES) project. J Adv Nurs. 2022;78(5):1305–16. https://doi.org/10.1111/jan.15141. Epub 2022 Jan 17.

    Article  PubMed  Google Scholar 

  124. Atkinson-Briggs S, Ryan C, Keech A, Jenkins A, Brazionis L. Centre of research excellence in diabetic retinopathy study group. Nurse-led vascular risk assessment in a regional Victorian indigenous primary care diabetes clinic: an integrated diabetes education and eye disease screening [iDEES] study. J Adv Nurs. 2022;78:3652. https://doi.org/10.1111/jan.15260. Epub ahead of print.

    Article  PubMed  Google Scholar 

  125. Gabbay RA, Kendall D, Beebe C, Cuddeback J, Hobbs T, Khan ND, Leal S, Miller E, Novak LM, Rajpathak SN, Scribner P, Meneghini L, Khunti K. Addressing therapeutic inertia in 2020 and beyond: a 3-year initiative of the American Diabetes Association. Clin Diabetes. 2020;38(4):371–81. https://doi.org/10.2337/cd20-0053.

    Article  PubMed  PubMed Central  Google Scholar 

  126. Akash MSH, Rehman K, Fiayyaz F, Sabir S, Khurshid M. Diabetes-associated infections: development of antimicrobial resistance and possible treatment strategies. Arch Microbiol. 2020;202(5):953–65. https://doi.org/10.1007/s00203-020-01818-x. Epub 2020 Feb 3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  127. Paul O, Arora P, Mayer M, Chatterjee S. Inflammation in periodontal disease: possible link to vascular disease. Front Physiol. 2021;11:609614. https://doi.org/10.3389/fphys.2020.609614.

    Article  PubMed  PubMed Central  Google Scholar 

  128. Nguyen ATM, Akhter R, Garde S, Scott C, Twigg SM, Colagiuri S, Ajwani S, Eberhard J. The association of periodontal disease with the complications of diabetes mellitus. A systematic review. Diabetes Res Clin Pract. 2020;165:108244. https://doi.org/10.1016/j.diabres.2020.108244. Epub 2020 Jun 8.

    Article  PubMed  Google Scholar 

  129. Dixon D, Edmonds M. Managing diabetic foot ulcers: pharmacotherapy for wound healing. Drugs. 2021;81(1):29–56. https://doi.org/10.1007/s40265-020-01415-8.

    Article  CAS  PubMed  Google Scholar 

  130. Rajamani K, Colman PG, Li LP, Best JD, Voysey M, D’Emden MC, Laakso M, Baker JR, Keech AC. FIELD study investigators. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet. 2009;373(9677):1780–8. https://doi.org/10.1016/S0140-6736(09)60698-X.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  131. Yuan J, Tan JTM, Rajamani K, Solly EL, King EJ, Lecce L, Simpson PJL, Lam YT, Jenkins AJ, Bursill CA, Keech AC, Ng MKC. Fenofibrate rescues diabetes-related impairment of ischemia-mediated angiogenesis by PPARα-independent modulation of thioredoxin-interacting protein. Diabetes. 2019;68(5):1040–53. https://doi.org/10.2337/db17-0926. Epub 2019 Feb 14.

    Article  CAS  PubMed  Google Scholar 

  132. Bornstein SR, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld AL, Boehm B, Amiel S, Holt RI, Skyler JS, DeVries JH, Renard E, Eckel RH, Zimmet P, Alberti KG, Vidal J, Geloneze B, Chan JC, Ji L, Ludwig B. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8(6):546–50. https://doi.org/10.1016/S2213-8587(20)30152-2. Epub 2020 Apr 23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  133. Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020;8(9):782–92. https://doi.org/10.1016/S2213-8587(20)30238-2. Epub 2020 Jul 17. Erratum in: Lancet Diabetes Endocrinol. 2020 Oct;8(10):e5. Erratum in: Lancet Diabetes Endocrinol. 2020 Nov;8(11):e6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Prattichizzo F, de Candia P, Nicolucci A, Ceriello A. Impact of pre-infection HbA1c levels on COVID-19 prognosis: systematic review and meta-analysis. Diabetes Metab Res Rev. 2021;38:e3476. https://doi.org/10.1002/dmrr.3476. Epub ahead of print.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  135. Chrvala CA, Sherr D, Lipman RD. Diabetes self-management education for adults with type 2 diabetes mellitus: a systematic review of the effect on glycemic control. Patient Educ Couns. 2016;99(6):926–43.

    Article  PubMed  Google Scholar 

  136. Chin J, Fulcher J, Jenkins A, Keech A. Is it time to repair a fairly fast Saab convertible? Testing an evidence-based mnemonic for the secondary prevention of cardiovascular disease. Heart Lung Circ. 2015;24(5):480–7.

    Article  PubMed  Google Scholar 

  137. Delbridge L, Mellor K, Ritchie R, Jenkins A. The heart’s performance when diabetes is the puppeteer. Diabetes Manage J. 2020.

    Google Scholar 

  138. McHugh K, DeVore AD, Wu J, Matsouaka RA, Fonarow GC, Heidenreich PA, Yancy CW, Green JB, Altman N, Hernandez AF. Heart failure with preserved ejection fraction and diabetes: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(5):602–11. https://doi.org/10.1016/j.jacc.2018.11.033.

    Article  PubMed  Google Scholar 

  139. Aune D, Schlesinger S, Neuenschwander M, Feng T, Janszky I, Norat T, Riboli E. Diabetes mellitus, blood glucose and the risk of heart failure: a systematic review and meta-analysis of prospective studies. Nutr Metab Cardiovasc Dis. 2018;28(11):1081–91. https://doi.org/10.1016/j.numecd.2018.07.005. Epub 2018 Jul 25.

    Article  CAS  PubMed  Google Scholar 

  140. Sohrabi C, Saberwal B, Lim WY, Tousoulis D, Ahsan S, Papageorgiou N. Heart failure in diabetes mellitus: an updated review. Curr Pharm Des. 2020;26(46):5933–52. https://doi.org/10.2174/1381612826666201118091659.

    Article  CAS  PubMed  Google Scholar 

  141. Jankauskas SS, Kansakar U, Varzideh F, Wilson S, Mone P, Lombardi A, Gambardella J, Santulli G. Heart failure in diabetes. Metabolism. 2021;125:154910. https://doi.org/10.1016/j.metabol.2021.154910. Epub 2021 Oct 8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  142. Park JJ. Epidemiology, pathophysiology, diagnosis and treatment of heart failure in diabetes. Diabetes Metab J. 2021;45(2):146–57. https://doi.org/10.4093/dmj.2020.0282. Epub 2021 Mar 25. Erratum in: Diabetes Metab J. 2021 Sep;45(5):796.

    Article  PubMed  PubMed Central  Google Scholar 

  143. Chia N, Fulcher J, Keech A. Beta-blocker, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, nitrate-hydralazine, diuretics, aldosterone antagonist, ivabradine, devices and digoxin (BANDAID(2)): an evidence-based mnemonic for the treatment of systolic heart failure. Intern Med J. 2016;46(6):653–62. https://doi.org/10.1111/imj.12839.

    Article  CAS  PubMed  Google Scholar 

  144. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart failure society of America. Circulation. 2017;136(6):e137–61.

    Article  PubMed  Google Scholar 

  145. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.

    Article  PubMed  Google Scholar 

  146. Ang L, Jaiswal M, Martin C, Pop-Busui R. Glucose control and diabetic neuropathy: Lessons from recent large clinical trials. Curr Diab Rep. 2014:14(9):528. https://doi.org/10.1007/s11892-014-0528-7.

Download references

Author information

Authors and Affiliations

  1. NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia

    Alicia J. Jenkins

  2. Department of Medicine, St. Vincent’s Hospital, The University of Melbourne, Melbourne, VIC, Australia

    Alicia J. Jenkins

  3. Department of Endocrinology and Diabetes, St. Vincent’s Hospital, Fitzroy, VIC, Australia

    Alicia J. Jenkins

  4. Diabetes and Vascular Medicine, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia

    Alicia J. Jenkins

Authors
  1. Alicia J. Jenkins
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alicia J. Jenkins .

Editor information

Editors and Affiliations

  1. NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia

    Alicia J. Jenkins

  2. Department of Medicine, Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Peter P. Toth

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Jenkins, A.J. (2023). Adjunct Drug Treatment to Reduce Vascular Disease in People with Diabetes. In: Jenkins, A.J., Toth, P.P. (eds) Lipoproteins in Diabetes Mellitus. Contemporary Diabetes. Humana, Cham. https://doi.org/10.1007/978-3-031-26681-2_29

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-26681-2_29

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-031-26680-5

  • Online ISBN: 978-3-031-26681-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation